Cosmos Health Inc. ([NASDAQ:COSM]) is a global healthcare company involved in developing and distributing pharmaceutical and health products. On April 10, 2026, the company reported its financial results. It announced an earnings per share of -$0.04, which aligned with analyst expectations, and revenue of $18.82 million, meeting the market consensus.
The reported revenue of $18.82 million reflects the company's continued operational performance. As highlighted by Accesswire, COSM confirms that geopolitical conflicts in the Middle East have not negatively affected its business or supply chain. The company also reaffirms its ongoing record revenue momentum and its expansion plans in the United States.
The earnings per share of -$0.04 indicates the company is not currently profitable. This aligns with its price-to-earnings (P/E) ratio of -0.50. A negative P/E ratio occurs when a company has negative earnings, meaning its expenses were greater than its income over a period. This is also shown by a negative earnings yield of -2.02.
Despite the net loss, COSM is focused on growth. Its U.S. expansion, featuring the NOOR collagen product, is projected to generate over $12 million in revenue within 12 months. The company also plans a Q2 2026 launch for Liv18™, a liver health supplement, to enter a U.S. market estimated to be worth over $7 billion.
The company's financial health includes a debt-to-equity ratio of 0.91, showing its debt is almost equal to the value owned by shareholders. A current ratio of 0.99 means its short-term assets are nearly sufficient to cover its short-term liabilities. An enterprise value-to-operating cash flow ratio of -3.08 indicates negative cash flow from its core business operations.
